πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 373 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9981944

GDF-8 inhibitors

Rigel Pharmaceuticals, Inc. Β· Granted Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9920041

Compositions and methods for inhibition of the JAK pathway

Rigel Pharmaceuticals, Inc. Β· Granted Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9913842

2,4-pyrimidinediamine compounds and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9913843

Protein kinase C inhibitors and uses thereof

Rigel Pharmaceuticals, Inc. Β· Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9890144

Compounds and method for treating autoimmune diseases

Rigel Pharmaceuticals, Inc. Β· Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9884868

TGF-beta inhibitors

Rigel Pharmaceuticals, Inc. Β· Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9878992

GDF-8 inhibitors

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9845311

Nrf2 activating compounds and uses thereof

Rigel Pharmaceuticals, Inc. Β· Granted Tue Dec 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9845512

Screening assay employing Dex and GDF8

Rigel Pharmaceuticals, Inc. Β· Granted Tue Dec 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9834568

Kinase inhibitors and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Dec 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9751893

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

Rigel Pharmaceuticals, Inc. Β· Granted Tue Sep 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9737554

Prodrugs of 2,4-pyrimidinediamine compounds and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Aug 22 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9732070

Protein kinase C inhibitors and uses thereof

Rigel Pharmaceuticals, Inc. Β· Granted Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9732073

Compositions and methods for inhibition of the JAK pathway

Rigel Pharmaceuticals, Inc. Β· Granted Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9730930

Treatment for vitiligo

Rigel Pharmaceuticals, Inc. Β· Granted Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9725419

Cycloalkyl substituted pyrimidinediamine compounds and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9701647

Tetrazolones as a carboxylic acid bioisosteres

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9682976

Protein kinase C inhibitors and uses thereof

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9663496

AMPK-activating heterocyclic compounds and methods for using the same

Rigel Pharmaceuticals, Inc. Β· Granted Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9650391

N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl

Rigel Pharmaceuticals, Inc. Β· Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9644224

Methods for cyclizing synthetic polymers

Rigel Pharmaceuticals, Inc. Β· Granted Tue May 09 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9624229

Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases

Rigel Pharmaceuticals, Inc. Β· Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9611260

Compositions and methods for inhibition of the JAK pathway

Rigel Pharmaceuticals, Inc. Β· Granted Tue Apr 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9598432

2,4-pyrimidinediamine compounds and uses as anti-proliferative agents

Rigel Pharmaceuticals, Inc. Β· Granted Tue Mar 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted